A medicine supply alert notice has been issued for Depakote® 500mg tablets and Depakote® 250mg tablets. The letter below outlines suggested actions for pharmacy teams.
Note: information in this MSAN only applies to the use of valproate semisodium in licensed indications i.e. the treatment of manic episodes in bipolar disorder when lithium is contraindicated or not tolerated. The continuation of treatment after manic episodes could be considered in patients who have responded to valproate semisodium for acute mania.
This circular is being shared under the Open Government Copyright licence. Whilst we will publish alerts relevant to pharmacists, pharmacy technicians and pharmacy teams we recommend you also keep an eye on the SHOW website.